Multivariable analysis using Cox regression to compare oncoplastic breast-conserving surgery + radiotherapy and mastectomy ± radiotherapy—HRs of overall survival and breast cancer-specific survival by treatment modality adjusted stepwise for patient demographics, socio-economic deprivation, tumour characteristics, staging, and treatment adjuncts
| . | Deaths . | HR (95% c.i.), P . | |||
|---|---|---|---|---|---|
| Model A . | Model B . | Model C . | Model D . | ||
| Overall survival | |||||
| OBCS + RTx | 37 (10.3) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 926 (31.4) | 2.38 (1.71,3.31), <0.001 | 2.26 (1.63,3.15), <0.001 | 1.70 (1.14,2.51), 0.008 | 1.72 (1.16,2.55), 0.007 |
| Mx − RTx | 734 (31.5) | 2.01 (1.44,2.80), <0.001 | 1.89 (1.35,2.64), <0.001 | 2.48 (1.67,3.67), <0.001 | 2.21 (1.49,3.27), <0.001 |
| Breast cancer-specific survival | |||||
| OBCS + RTx | 26 (7.2) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 604 (20.5) | 2.51 (1.69,3.72), <0.001 | 2.42 (1.63,3.60), <0.001 | 1.72 (1.05,2.83), 0.031 | 1.74 (1.06,2.86), 0.028 |
| Mx − RTx | 246 (10.5) | 1.28 (0.85,1.92), 0.243 | 1.22 (0.81,1.84), 0.341 | 2.06 (1.24,3.42), 0.005 | 1.89 (1.13,3.14), 0.015 |
| . | Deaths . | HR (95% c.i.), P . | |||
|---|---|---|---|---|---|
| Model A . | Model B . | Model C . | Model D . | ||
| Overall survival | |||||
| OBCS + RTx | 37 (10.3) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 926 (31.4) | 2.38 (1.71,3.31), <0.001 | 2.26 (1.63,3.15), <0.001 | 1.70 (1.14,2.51), 0.008 | 1.72 (1.16,2.55), 0.007 |
| Mx − RTx | 734 (31.5) | 2.01 (1.44,2.80), <0.001 | 1.89 (1.35,2.64), <0.001 | 2.48 (1.67,3.67), <0.001 | 2.21 (1.49,3.27), <0.001 |
| Breast cancer-specific survival | |||||
| OBCS + RTx | 26 (7.2) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 604 (20.5) | 2.51 (1.69,3.72), <0.001 | 2.42 (1.63,3.60), <0.001 | 1.72 (1.05,2.83), 0.031 | 1.74 (1.06,2.86), 0.028 |
| Mx − RTx | 246 (10.5) | 1.28 (0.85,1.92), 0.243 | 1.22 (0.81,1.84), 0.341 | 2.06 (1.24,3.42), 0.005 | 1.89 (1.13,3.14), 0.015 |
Values are n (%) unless otherwise indicated. Model A: adjusted for age, year of diagnosis, and mode of referral. Model B: adjusted for the same variables as model A + socio-economic deprivation. Model C: adjusted for the same variables as model B + tumour grade, tumour size, receptor profile, and lymph node status (pathological staging for primary surgery patients and clinical staging for neoadjuvant chemotherapy patients). Model D: adjusted for the same variables as model C + treatment adjuncts (chemotherapy, biological therapy, and/or endocrine therapy). OBCS, oncoplastic breast-conserving surgery; RTx, radiotherapy; MTx, mastectomy.
Multivariable analysis using Cox regression to compare oncoplastic breast-conserving surgery + radiotherapy and mastectomy ± radiotherapy—HRs of overall survival and breast cancer-specific survival by treatment modality adjusted stepwise for patient demographics, socio-economic deprivation, tumour characteristics, staging, and treatment adjuncts
| . | Deaths . | HR (95% c.i.), P . | |||
|---|---|---|---|---|---|
| Model A . | Model B . | Model C . | Model D . | ||
| Overall survival | |||||
| OBCS + RTx | 37 (10.3) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 926 (31.4) | 2.38 (1.71,3.31), <0.001 | 2.26 (1.63,3.15), <0.001 | 1.70 (1.14,2.51), 0.008 | 1.72 (1.16,2.55), 0.007 |
| Mx − RTx | 734 (31.5) | 2.01 (1.44,2.80), <0.001 | 1.89 (1.35,2.64), <0.001 | 2.48 (1.67,3.67), <0.001 | 2.21 (1.49,3.27), <0.001 |
| Breast cancer-specific survival | |||||
| OBCS + RTx | 26 (7.2) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 604 (20.5) | 2.51 (1.69,3.72), <0.001 | 2.42 (1.63,3.60), <0.001 | 1.72 (1.05,2.83), 0.031 | 1.74 (1.06,2.86), 0.028 |
| Mx − RTx | 246 (10.5) | 1.28 (0.85,1.92), 0.243 | 1.22 (0.81,1.84), 0.341 | 2.06 (1.24,3.42), 0.005 | 1.89 (1.13,3.14), 0.015 |
| . | Deaths . | HR (95% c.i.), P . | |||
|---|---|---|---|---|---|
| Model A . | Model B . | Model C . | Model D . | ||
| Overall survival | |||||
| OBCS + RTx | 37 (10.3) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 926 (31.4) | 2.38 (1.71,3.31), <0.001 | 2.26 (1.63,3.15), <0.001 | 1.70 (1.14,2.51), 0.008 | 1.72 (1.16,2.55), 0.007 |
| Mx − RTx | 734 (31.5) | 2.01 (1.44,2.80), <0.001 | 1.89 (1.35,2.64), <0.001 | 2.48 (1.67,3.67), <0.001 | 2.21 (1.49,3.27), <0.001 |
| Breast cancer-specific survival | |||||
| OBCS + RTx | 26 (7.2) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Mx + RTx | 604 (20.5) | 2.51 (1.69,3.72), <0.001 | 2.42 (1.63,3.60), <0.001 | 1.72 (1.05,2.83), 0.031 | 1.74 (1.06,2.86), 0.028 |
| Mx − RTx | 246 (10.5) | 1.28 (0.85,1.92), 0.243 | 1.22 (0.81,1.84), 0.341 | 2.06 (1.24,3.42), 0.005 | 1.89 (1.13,3.14), 0.015 |
Values are n (%) unless otherwise indicated. Model A: adjusted for age, year of diagnosis, and mode of referral. Model B: adjusted for the same variables as model A + socio-economic deprivation. Model C: adjusted for the same variables as model B + tumour grade, tumour size, receptor profile, and lymph node status (pathological staging for primary surgery patients and clinical staging for neoadjuvant chemotherapy patients). Model D: adjusted for the same variables as model C + treatment adjuncts (chemotherapy, biological therapy, and/or endocrine therapy). OBCS, oncoplastic breast-conserving surgery; RTx, radiotherapy; MTx, mastectomy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
